Clinical Trials Browser

Terminated × INDUSTRY × tovorafenib × Clear all

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07121829 2025-08-14

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Phase 1 Terminated

44 enrolled

CNSDermatologicGastrointestinalThoracic

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

Dermatologic

Melanoma

Clinical Trials

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma